RGEN Repligen Corporation
USHealthcareAs of 2026-07-10 16:00
Why RGEN matters now
Repligen Corporation (RGEN) is a US stock in Healthcare. The latest InvestLog snapshot shows $144.24 with +0.21% on the session and $8.14B in market capitalization; recent performance reads 1-month +21.66% and YTD -19.43%.
The latest financial table shown here is Q1 2026, with revenue of $194.3M, net income of $8.3M, and EPS of $0.15. Investors can compare that operating picture with valuation signals such as P/E 132.83 and FCF yield 1.4%.
The latest indexable market news headline is "Here Are Tuesday’s Best Wall Street Analyst Research Calls: Adobe, American Airlines, Broadcom, First Solar, Meta Platforms, Shopify, Space-X, Ventas, Waste Managment, and More" from 247 Wallst.
Additional event context on this page matters because analyst consensus is Buy with a median target of $152.50; recent insider activity includes BARTHELEMY NICOLAS filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
132.83
PEG
0.46
P/B
3.53
P/S
9.76
EV/EBITDA
43.77
DCF Value
$31.18
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.3%
Operating Margin
8.8%
Net Margin
6.7%
ROE
2.5%
ROA
1.8%
ROIC
2.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $194.3M | $8.3M | $0.15 |
| Q4 2025 | $197.9M | $13.3M | $0.23 |
| FY 2025 | $738.3M | $48.9M | $0.86 |
| Q3 2025 | $188.8M | $14.9M | $0.26 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$158.67
Target (Median)
$152.50
Target Range
$142.00 - $200.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.08
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.